These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32416645)

  • 1. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Newton KP; Lavine JE; Wilson L; Behling C; Vos MB; Molleston JP; Rosenthal P; Miloh T; Fishbein MH; Jain AK; Murray KF; Schwimmer JB;
    Hepatology; 2021 Mar; 73(3):937-951. PubMed ID: 32416645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
    Schwimmer JB; Lavine JE; Wilson LA; Neuschwander-Tetri BA; Xanthakos SA; Kohli R; Barlow SE; Vos MB; Karpen SJ; Molleston JP; Whitington PF; Rosenthal P; Jain AK; Murray KF; Brunt EM; Kleiner DE; Van Natta ML; Clark JM; Tonascia J; Doo E;
    Gastroenterology; 2016 Dec; 151(6):1141-1154.e9. PubMed ID: 27569726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.
    Gawrieh S; Wilson LA; Cummings OW; Clark JM; Loomba R; Hameed B; Abdelmalek MF; Dasarathy S; Neuschwander-Tetri BA; Kowdley K; Kleiner D; Doo E; Tonascia J; Sanyal A; Chalasani N;
    Am J Gastroenterol; 2019 Oct; 114(10):1626-1635. PubMed ID: 31517638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
    Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
    PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
    Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
    Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
    Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
    Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.
    Xanthakos SA; Lavine JE; Yates KP; Schwimmer JB; Molleston JP; Rosenthal P; Murray KF; Vos MB; Jain AK; Scheimann AO; Miloh T; Fishbein M; Behling CA; Brunt EM; Sanyal AJ; Tonascia J;
    Gastroenterology; 2020 Nov; 159(5):1731-1751.e10. PubMed ID: 32712103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study.
    Chen LW; Huang MS; Shyu YC; Chien RN
    Kaohsiung J Med Sci; 2021 Sep; 37(9):819-827. PubMed ID: 34002481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
    Dixon JB; Bhathal PS; O'Brien PE
    Obes Surg; 2006 Oct; 16(10):1278-86. PubMed ID: 17059735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.
    Neuschwander-Tetri BA; Clark JM; Bass NM; Van Natta ML; Unalp-Arida A; Tonascia J; Zein CO; Brunt EM; Kleiner DE; McCullough AJ; Sanyal AJ; Diehl AM; Lavine JE; Chalasani N; Kowdley KV;
    Hepatology; 2010 Sep; 52(3):913-24. PubMed ID: 20648476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
    Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease.
    Shukla A; Kapileswar S; Gogtay N; Joshi A; Dhore P; Shah C; Abraham P; Bhatia S
    Indian J Gastroenterol; 2015 Jul; 34(4):281-5. PubMed ID: 26341864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
    Patton HM; Lavine JE; Van Natta ML; Schwimmer JB; Kleiner D; Molleston J;
    Gastroenterology; 2008 Dec; 135(6):1961-1971.e2. PubMed ID: 19013463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
    Chan WK; Ida NH; Cheah PL; Goh KL
    J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.